Prostaglandin E2 and bethanechol in combination for treating detrusor underactivity

Area of Science:

• Urology
• Pharmacology
• Clinical Trials

Background:

• Detrusor underactivity impairs bladder emptying, often necessitating clean intermittent self-catheterization (CISC).
• Intravesical prostaglandin E2 (PGE2) and oral bethanechol chloride (BC) have been used individually for detrusor underactivity with limited success.
• Investigating combination therapy may reveal synergistic effects for improved bladder function.

Purpose of the Study:

• To evaluate the additive or synergistic effects of combining intravesical PGE2 and oral BC.
• To assess the efficacy of this combination in improving bladder emptying in patients with detrusor underactivity.
• To compare the combination therapy against a placebo in a randomized, double-blind study.

Main Methods:

• A prospective, randomized, double-blind study involving 19 patients with detrusor underactivity and postvoid residual urine volumes (PVR) > 300 mL.
• The experimental group (n=9) received weekly intravesical PGE2 plus daily oral BC for 6 weeks.
• The control group (n=10) received weekly intravesical saline plus daily placebo tablets for 6 weeks.

Main Results:

• The combination group showed a statistically significant decrease in median PVR from 426 mL to 325 mL (P < 0.015).
• The placebo group showed no significant change in median PVR (576 mL to 538 mL, P = 0.09).
• Four patients in the combination group reported symptomatic improvement and reduced CISC frequency.

Conclusions:

• The combination of BC and PGE2 demonstrated a pharmacological effect on bladder emptying but offered limited therapeutic benefit over placebo.
• While not recommended for routine use, this combination may be considered for select patients with detrusor underactivity.
• Further research may be needed to optimize treatment strategies for impaired detrusor contractility.